

Special Issue

Adenovirus Cell and Immune Interactions 2.0

Message from the Guest Editor

Ever since the discovery in the early 1950s, human adenoviruses, the cause of respiratory diseases of young children, have been the subject of intense basic research as well as efforts to engineer HAdV vectors to ameliorate human diseases. Though much information has been gleaned over the past 67 years from laboratory and clinical investigations, we still have an incomplete picture of the critical associations of HAdV with host cells and specific components of immune system. Each contribution in the SI will highlight the progress made to acquire basic knowledge of HAdV host interactions and will indicate particular areas uncovered. Topics in the new SI include key steps in HAdV–host cell entry and immune interactions as well as structure-based investigations of virus and virus capsid protein associations with cell receptors and innate immune molecules. Involvement of HAd in human diseases such as ocular pathogenesis will be also described. Genetic and chemical approaches to alter the Ad capsid to avoid immune interactions as well as structural and functional analyses of “immunoprivileged” HAdV26 and HAd49 vaccine candidate vectors will also be discussed.

Guest Editor

Prof. Dr. Glen R. Nemerow

Department of Immunology and Microbial Science, Scripps Research Institute, La Jolla, CA 92037, USA

Deadline for manuscript submissions

closed (15 June 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/107518

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).